New nOPV2 Oral Polio Vaccine: Enhanced Genetic Stability for Safer Eradication

New Oral Poliovirus Vaccine nOPV2 Shows Improved Genetic Stability to Reduce Vaccine-Derived Strain Risks Researchers have identified notable advancements in the genetic stability and safety profile of a novel live-attenuated oral poliovirus type 2 vaccine (nOPV2). The findings highlight the vaccine’s increased stability when compared to neurovirulent strains, which pose ongoing challenges in global efforts to eradicate poliovirus. This development comes as health authorities continue to address outbreaks of poliovirus, particularly in regions where vaccination coverage remains inconsistent. The study examined the genetic composition and performance of nOPV2, emphasizing its ability to maintain stability under conditions that typically lead to mutations in traditional oral poliovirus vaccines. Researchers noted that this enhanced stability reduces the risk of vaccine-derived poliovirus strains emerging, a key concern with previous vaccines. The findings suggest that nOPV2 could play a significant role in mitigating risks associated with current vaccination strategies while supporting global eradication campaigns. Newsflash | Powered by GeneOnline AI Source: GO-AI-ne1 For any suggestion and feedback, please contact us. Date: January 19, 2026